Latest news with #PrashantWarier
Business Wire
26-06-2025
- Business
- Business Wire
Qure.ai Recognized Among TIME's 100 Most Influential Companies of 2025
NEW YORK--(BUSINESS WIRE)-- the world's most widely adopted digital health innovator, has been named to TIME's 2025 TIME100 Most Influential Companies list. Now in its fifth year, the TIME100 list highlights companies making an extraordinary global impact through innovation, ambition, and measurable success. TIME's editorial spotlighted work in advancing diagnostic equity through AI, stating: 'Trained on one of the world's largest data sets, algorithms are as accurate as a radiologist, according to the company, providing crucial insights in rural or developing areas where specialists may not be available. tools have now been deployed in more than 100 countries, and the company has 18 FDA clearances—the greatest number for lung cancer AI in the U.S.—including three new approvals in 2024.' was selected alongside iconic and dynamic brands such as Abbott, Midi Health, Vertex Pharmaceuticals, Function Health, Gilead, CRISPR Therapeutics, NBBJ, and Northwell Health, and is featured in the Pioneer category among health tech AI firms on the 2025 list. Speaking on the recognition, Prashant Warier, CEO and Founder said, 'To be named among TIME's 100 Most Influential Companies is an acknowledgment of a simple but urgent belief: that access to timely, high-quality diagnostics should not depend on where you live. This honor reflects the dedication of our teams and partners across continents, working to close the gap between innovation and impact. This recognition pushes us to keep advancing that future, where care begins long before crisis.' This milestone recognition follows a pivotal year for marked by accelerated momentum in the United States. With over 18 FDA-cleared findings and the launch of its Lung Cancer Care Continuum, a portfolio of AI solutions to detect, measure, and manage lung nodules; now offers an end-to-end suite that supports earlier lung cancer diagnosis across diverse care settings. Backed by a strategic Series D round led by global investors including Lightspeed, 360 One Asset, and the Merck Global Health Innovation Fund, the company is scaling its commercial and clinical impact worldwide. On the global front, continues to lead in innovation for low- and middle-income countries, drawing on its deep experience in TB surveillance at scale. Its newest offering, Aira, a multi-disease clinical AI co-pilot, was launched at the World Health Assembly in Geneva to support care coordination in resource-constrained settings. To compile this year's TIME100 list, TIME's editors evaluated nominees across sectors based on impact, innovation, ambition, and success, after polling its global network of journalists and outside experts. The final list spotlights 105 companies helping chart a path forward for the world. See the full list here: About is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Neurocritical conditions to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
Time of India
23-05-2025
- Health
- Time of India
Qure.ai launches AI tool to aid health workers in LMICs
Mumbai: AI solution provider company has introduced AIRA, an AI-powered co-pilot tool for frontline healthcare workers in low- and middle-income countries (LMICs) at the 78th World Health Assembly in Geneva this week. The company states that community health workers spend over 40 per cent of their time on manual data collection, yet many countries still lack sufficient population-level data for decision-making. According to the company, AIRA is designed to ease the burden on healthcare workers by automating symptom and patient history collection, supporting adherence to clinical protocols, and generating population-level health insights . It aims to address key challenges in LMICs, including a projected shortage of 11 million health workers by 2030 and the 17 million preventable deaths that occur annually. 'With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems,' said Prashant Warier, CEO and Founder,
Zawya
23-05-2025
- Health
- Zawya
‘AIRA' an AI Co-Pilot for Health Workers in LMICs launched during the World Health Assembly 2025
Leveraging its strength in digital health innovation, has launched a new AI-powered co-pilot tool for frontline healthcare workers in resource-constrained geographies this week during the 78th World Health Assembly in Geneva. 'AIRA' is designed to optimize limited healthcare resources in Low- and Middle-Income Countries (LMICs) by supporting AI-enabled digitization of symptoms and patient history collection; clinical protocol adherence and decision support; and aggregated population health insights. There are 17 million preventable deaths in LMICs and an estimated shortage of 11 million health workers by 20301. At the same time, more than 40% of community health workers' time is spent on manual data collection, and yet countries do not have population-level data to make informed decisions. AIRA aims to solve this urgent need by freeing up precious health worker time to engage more with patients, while digitizing data automatically. Speaking at the World Health Assembly side-event on AI, Prashant Warier, CEO and Founder of said, 'With AI, we can make a seismic shift towards health equity in LMICs. AIRA in the hands of every healthcare worker will free up their time for more patient interactions via automated data collection and better clinical protocol adherence. With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems. We have demonstrated this in our last 10 years in TB and are motivated to do the same now for primary healthcare.' Dr. Michel Sidibé, Special Envoy at the African Union, said, 'Health ministries in developing nations need to deliver healthcare to their populations at a fraction of the budget compared to developed countries. We have to be creative to make this happen. Digital health and AI are most certainly catalysts to improve efficiency, access, and quality of care.' AIRA is an AI co-pilot for healthcare workers in LMICs. It is built on Large Language Models (LLMs) with a deep understanding of Low- and Middle-Income Country health systems and needs. It is designed to reduce administrative workload and free up time for better patient care, while enabling better protocol adherence and population insights. About is a health tech company that uses deep learning and Artificial Intelligence (AI) to make healthcare more accessible and equitable for patients worldwide. Our solutions power the efficient identification and management of Tuberculosis (TB), Lung Cancer and Stroke to support clinicians and propel developments in the pharmaceutical and medical device industries. We empower healthcare by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.
Time of India
20-05-2025
- Business
- Time of India
Healthcare AI startup Qure. AI aiming for IPO in two years, CEO says
Qure. AI provides AI solutions in diagnostics for early detection of tuberculosis, lung cancer and stroke risks. Its global clients include AstraZeneca, and Medtronic and Johnson and Johnson MedTech in India. The global market for AI in healthcare, valued at $14.92 billion in 2024, is expected to grow to $110 billion by 2030, according to market estimates. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Qure. AI, an India-based startup providing artificial intelligence tools to healthcare firms, is aiming to turn profitable in the next financial year and for an initial public offer ( IPO ) in two years, its CEO told company, founded in 2016 and largely backed by AI firm Fractal Analytics, counts Peak XV Partners and Novo Nordisk's Novo Holdings among its investors, and has raised $125 million in funding so far, CEO Prashant Warier said."We look to break even and be profitable next financial year. As we sort of get to that can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO," he said last declined to elaborate on the firm's valuation. The firm was valued at $264 million as of November 2024, according to data from market intelligence platform AI provides AI solutions in diagnostics for early detection of tuberculosis, lung cancer and stroke risks. Its global clients include AstraZeneca , and Medtronic and Johnson and Johnson MedTech in global market for AI in healthcare , valued at $14.92 billion in 2024, is expected to grow to $110 billion by 2030, according to market is being rapidly adopted by healthcare service providers around the world for early detection of diseases and to streamline work for overburdened professionals, according to industry experts."We're growing at a rate of 60%-70% every year (in revenue) and I think we probably will accelerate in the next five years," Warier said, adding that they serve around 15 million patients derives about 25% of revenue from the United States, which is its largest market, and is also eyeing expansion in the market with further partnerships, he company also is focusing on on low-and middle-income countries in Latin America and Africa. India, however, is a much smaller market for the firm, contributing less than 5% of revenue.
The Star
20-05-2025
- Business
- The Star
Indian healthcare AI startup Qure.AI aiming for IPO in two years, CEO says
AI (Artificial Intelligence) letters are placed on computer motherboard in this illustration taken, June 23, 2023. REUTERS/Dado Ruvic/Illustration (Reuters) - an India-based startup providing artificial intelligence tools to healthcare firms, is aiming to turn profitable in the next financial year and for an initial public offer (IPO) in two years, its CEO told Reuters. The company, founded in 2016 and largely backed by AI firm Fractal Analytics, counts Peak XV Partners and Novo Nordisk's Novo Holdings among its investors, and has raised $125 million in funding so far, CEO Prashant Warier said. "We look to break even and be profitable next financial year. As we sort of get to that can start planning. And maybe in two-and-a-half years or two years is the earliest we can do an IPO," he said last week. He declined to elaborate on the firm's valuation. The firm was valued at $264 million as of November 2024, according to data from market intelligence platform Tracxn. provides AI solutions in diagnostics for early detection of tuberculosis, lung cancer and stroke risks. Its global clients include AstraZeneca, and Medtronic and Johnson and Johnson MedTech in India. The global market for AI in healthcare, valued at $14.92 billion in 2024, is expected to grow to $110 billion by 2030, according to market estimates. AI is being rapidly adopted by healthcare service providers around the world for early detection of diseases and to streamline work for overburdened professionals, according to industry experts. "We're growing at a rate of 60%-70% every year (in revenue) and I think we probably will accelerate in the next five years," Warier said, adding that they serve around 15 million patients annually. QureAI derives about 25% of revenue from the United States, which is its largest market, and is also eyeing expansion in the market with further partnerships, he said. The company also is focusing on on low-and middle-income countries in Latin America and Africa. India, however, is a much smaller market for the firm, contributing less than 5% of revenue. (Reporting by Rishika Sadam; Editing by Varun H K)
